Legal Challenge Launched to Halt UK Puberty Blocker Trial for Children
A contentious clinical trial aimed at improving care for gender-questioning children is facing a legal challenge from concerned campaigners, raising fresh questions about the safety and efficacy of puberty blockers.
A legal process has begun seeking to suspend the NHS-funded “Pathways” trial, arguing the research poses potential harm to vulnerable young participants. The challenge follows last year’s landmark review of gender identity services led by Dr. Hilary Cass, which highlighted a significant lack of robust evidence in the field of gender medicine and described existing practices as being “built on shaky foundations.”
Cass Review Fuels Debate Over Puberty Blockers
Until recently, puberty blockers – originally developed to treat early-onset puberty – were prescribed “off-label” to children experiencing gender dysphoria. However, the NHS halted this practice following the Cass review’s findings. The review underscored the need for more rigorous research to understand the long-term effects of these treatments, particularly on young people’s development.
Legal letters have been dispatched to the medical regulators overseeing the trial, and also copied to Health Secretary Wes Streeting and NHS England. The action is spearheaded by the Bayswater Support Group, comprised of parents of children and young adults who identify as trans or non-binary, alongside psychotherapist James Esses, who specializes in treating children with gender dysphoria, and Keira Bell, a detransitioner who previously received puberty blockers as a teenager.
Concerns Over Safety and Irreversible Effects
Campaigners assert the trial “fails to safeguard the rights, safety and wellbeing of its subjects, who constitute highly vulnerable children.” A central concern revolves around the potential for irreversible damage to fertility as a result of the treatment. They further contend the research is “unlawful given the limited known benefits of treatment with puberty blockers.”
Esses questioned the reliance on pharmaceutical intervention, stating that counseling has demonstrated effectiveness in supporting children with gender dysphoria.
Details of the Pathways Trial
The Pathways trial, revealed last month, is scheduled to commence in January. Conducted by researchers at King’s College London, the study aims to evaluate methods for enhancing care for gender-questioning children. Approximately 226 young people are expected to participate over the next three years, with eligibility extending to those as young as 10 or 11 (for biological girls) and 11 or 12 (for boys). The upper age limit for enrollment is 15 years and 11 months.
The trial will divide participants into two groups: one receiving puberty blockers for two years, and the other receiving the drugs after a one-year delay. Researchers anticipate publishing their findings in approximately four years.
Regulatory Response and Previous Legal Challenges
Preliminary legal documents have been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA), which approved the trial, and the Health Research Authority (HRA), responsible for protecting participants in medical research. Both organizations have indicated they are unable to comment on ongoing legal proceedings. However, the HRA affirmed that the trial possesses “all the necessary regulatory approvals that it needs to begin.”
Bell previously led a 2020 judicial review concerning the now-defunct gender identity development service at the Tavistock Centre in London. The review questioned whether children under 16 possessed the maturity to provide informed consent for puberty blocker prescriptions.
Bell expressed her belief that the trial would be detrimental to children, recounting her own experience with puberty blockers as deeply regrettable. “I didn’t know that I was essentially trapping my own mind from developing, because puberty doesn’t happen in a vacuum. It’s your whole body, it’s your brain sending signals to your body. So I didn’t understand any of that,” she shared with the BBC. She also questioned why the NHS isn’t prioritizing studies focused on individuals who have already undergone puberty blocker treatment, stating, “There are children who have already been down this pathway. I’m one of them. Why aren’t we doing follow-ups with people like me?”
Government and Expert Perspectives
Health Secretary Wes Streeting has previously stated the trial would “provide better evidence for how the NHS can support and treat young people with gender incongruence.” In a November statement to parliament, he acknowledged the sensitivity of the issue, recognizing “understandable concerns around safety, efficacy and consent,” while emphasizing the presence of “strict eligibility criteria in place, including clinical review and parental consent.”
Jonathan Montgomery, a professor of healthcare law at University College London who advised the study team on legal and ethical compliance, argued that the NHS’s updated gender services now incorporate improved safeguarding measures and no longer automatically assume puberty suppression is the appropriate course of action, instead offering a broader range of treatments.
“Young people and their families have been let down by a collective failure to generate the science that would enable them to take informed decisions,” Montgomery said. “Baroness Cass recognised that research is needed to remedy that failure. Blocking all such research would compound these past wrongs.”
A Department of Health and Social Care spokesperson affirmed that “This trial will help provide the evidence that is currently lacking. Its approval came only after extremely rigorous safety checks and with multiple safeguards in place to protect young people’s wellbeing, including clinical and parental approval.”
